Pyxis Oncology, Inc.

PYXS · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders13.5%

Institutions42.5%

Income Statement

	2025-12-31	2024-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$13.86M	$16.15M	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$2.39M	$475000	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$84.42M	-$89.46M	-$69.72M
Operating income as a percentage of revenue.	-609.2%	-554.1%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$79.62M	-$77.33M	-$75.97M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.28	$-1.32	$-8.95
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.28	$-1.32	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$15.42M	$19.47M	$274.70M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$91.52M	$157.18M	$280.02M
Everything the company owes — debt, unpaid bills, and other obligations.	$38.11M	$36.43M	$18.71M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$53.41M	$120.75M	$261.31M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$63.50M	-$57.67M	-$35.33M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$9000	$237000	$540000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$63.51M	-$57.91M	-$35.87M

	You	Peer avg
P/E	–	15.5
Revenue Growth	–	+881.0%
ROE	-179.1%	-33.5%

Pyxis Oncology, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison